iBio, Inc.: director Arkowitz David received 38,000 shares

What happened Arkowitz David, a director of iBio, Inc., received a grant of 38,000 derivative securities (reported as a grant/award) on Oct 14, 2026. The filing reports an acquisition price of $0.00 and a reported value of $0.

Key details

• Transaction date and price: Oct 14, 2026 at $0.00 per share; transaction code A (award/grant).
• Security type: derivative (options), reported as acquired.
• Shares owned after the transaction: not stated in the filing excerpt provided.
• Vesting: per footnote, the options vest pro rata in monthly installments over 12 months, with the first installment vesting one month after the grant date, subject to continued service.
• Filing date: Oct 15, 2026 (reporting the Oct 14, 2026 transaction).

Why it may matter This filing reports a grant of options that are subject to a 12-month monthly vesting schedule; it is not a market sale. A filing does not show why the insider traded or why the company acted.